These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 24725940

  • 1. Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein.
    Bates JT, Keefer CJ, Slaughter JC, Kulp DW, Schief WR, Crowe JE.
    Virology; 2014 Apr; 454-455():139-44. PubMed ID: 24725940
    [Abstract] [Full Text] [Related]

  • 2. Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater In Vivo Protection than the Murine Precursor of Palivizumab.
    Zhao M, Zheng ZZ, Chen M, Modjarrad K, Zhang W, Zhan LT, Cao JL, Sun YP, McLellan JS, Graham BS, Xia NS.
    J Virol; 2017 Aug 01; 91(15):. PubMed ID: 28539438
    [Abstract] [Full Text] [Related]

  • 3. Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.
    Mousa JJ, Sauer MF, Sevy AM, Finn JA, Bates JT, Alvarado G, King HG, Loerinc LB, Fong RH, Doranz BJ, Correia BE, Kalyuzhniy O, Wen X, Jardetzky TS, Schief WR, Ohi MD, Meiler J, Crowe JE.
    Proc Natl Acad Sci U S A; 2016 Nov 01; 113(44):E6849-E6858. PubMed ID: 27791117
    [Abstract] [Full Text] [Related]

  • 4. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers.
    Swanson KA, Settembre EC, Shaw CA, Dey AK, Rappuoli R, Mandl CW, Dormitzer PR, Carfi A.
    Proc Natl Acad Sci U S A; 2011 Jun 07; 108(23):9619-24. PubMed ID: 21586636
    [Abstract] [Full Text] [Related]

  • 5. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab.
    Zhu Q, McAuliffe JM, Patel NK, Palmer-Hill FJ, Yang CF, Liang B, Su L, Zhu W, Wachter L, Wilson S, MacGill RS, Krishnan S, McCarthy MP, Losonsky GA, Suzich JA.
    J Infect Dis; 2011 Mar 01; 203(5):674-82. PubMed ID: 21208913
    [Abstract] [Full Text] [Related]

  • 6. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
    Gilbert BE, Patel N, Lu H, Liu Y, Guebre-Xabier M, Piedra PA, Glenn G, Ellingsworth L, Smith G.
    Vaccine; 2018 Dec 18; 36(52):8069-8078. PubMed ID: 30389195
    [Abstract] [Full Text] [Related]

  • 7. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion.
    Huang K, Incognito L, Cheng X, Ulbrandt ND, Wu H.
    J Virol; 2010 Aug 18; 84(16):8132-40. PubMed ID: 20519399
    [Abstract] [Full Text] [Related]

  • 8. Structural basis of respiratory syncytial virus neutralization by motavizumab.
    McLellan JS, Chen M, Kim A, Yang Y, Graham BS, Kwong PD.
    Nat Struct Mol Biol; 2010 Feb 18; 17(2):248-50. PubMed ID: 20098425
    [Abstract] [Full Text] [Related]

  • 9. Reversion of somatic mutations of the respiratory syncytial virus-specific human monoclonal antibody Fab19 reveal a direct relationship between association rate and neutralizing potency.
    Bates JT, Keefer CJ, Utley TJ, Correia BE, Schief WR, Crowe JE.
    J Immunol; 2013 Apr 01; 190(7):3732-9. PubMed ID: 23455501
    [Abstract] [Full Text] [Related]

  • 10. Neutralizing epitopes of RSV and palivizumab resistance in Japan.
    Hashimoto K, Hosoya M.
    Fukushima J Med Sci; 2017 Dec 19; 63(3):127-134. PubMed ID: 28867684
    [Abstract] [Full Text] [Related]

  • 11. Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus.
    Wen X, Mousa JJ, Bates JT, Lamb RA, Crowe JE, Jardetzky TS.
    Nat Microbiol; 2017 Jan 30; 2():16272. PubMed ID: 28134915
    [Abstract] [Full Text] [Related]

  • 12. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody.
    McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, Zhou T, Baxa U, Yasuda E, Beaumont T, Kumar A, Modjarrad K, Zheng Z, Zhao M, Xia N, Kwong PD, Graham BS.
    Science; 2013 May 31; 340(6136):1113-7. PubMed ID: 23618766
    [Abstract] [Full Text] [Related]

  • 13. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
    Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA.
    J Mol Biol; 2007 May 04; 368(3):652-65. PubMed ID: 17362988
    [Abstract] [Full Text] [Related]

  • 14. Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab.
    Zhu Q, Patel NK, McAuliffe JM, Zhu W, Wachter L, McCarthy MP, Suzich JA.
    J Infect Dis; 2012 Feb 15; 205(4):635-8. PubMed ID: 22184728
    [Abstract] [Full Text] [Related]

  • 15. Antigenic Site-Specific Competitive Antibody Responses to the Fusion Protein of Respiratory Syncytial Virus Were Associated With Viral Clearance in Hematopoietic Cell Transplantation Adults.
    Ye X, Iwuchukwu OP, Avadhanula V, Aideyan LO, McBride TJ, Ferlic-Stark LL, Patel KD, Piedra FA, Shah DP, Chemaly RF, Piedra PA.
    Front Immunol; 2019 Feb 15; 10():706. PubMed ID: 30984206
    [Abstract] [Full Text] [Related]

  • 16. Relationship between the loss of neutralizing antibody binding and fusion activity of the F protein of human respiratory syncytial virus.
    Liu C, Day ND, Branigan PJ, Gutshall LL, Sarisky RT, Del Vecchio AM.
    Virol J; 2007 Jul 10; 4():71. PubMed ID: 17623075
    [Abstract] [Full Text] [Related]

  • 17. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization.
    Wu H, Pfarr DS, Tang Y, An LL, Patel NK, Watkins JD, Huse WD, Kiener PA, Young JF.
    J Mol Biol; 2005 Jul 01; 350(1):126-44. PubMed ID: 15907931
    [Abstract] [Full Text] [Related]

  • 18. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection.
    Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, Millar A, Power UF, Stortelers C, Allosery K, Melero JA, Depla E.
    Antimicrob Agents Chemother; 2016 Jan 01; 60(1):6-13. PubMed ID: 26438495
    [Abstract] [Full Text] [Related]

  • 19. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats.
    Smith G, Raghunandan R, Wu Y, Liu Y, Massare M, Nathan M, Zhou B, Lu H, Boddapati S, Li J, Flyer D, Glenn G.
    PLoS One; 2012 Jan 01; 7(11):e50852. PubMed ID: 23226404
    [Abstract] [Full Text] [Related]

  • 20. Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge.
    Schickli JH, Whitacre DC, Tang RS, Kaur J, Lawlor H, Peters CJ, Jones JE, Peterson DL, McCarthy MP, Van Nest G, Milich DR.
    J Clin Invest; 2015 Apr 01; 125(4):1637-47. PubMed ID: 25751145
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.